HomeCompareOBCI vs JNJ

OBCI vs JNJ: Dividend Comparison 2026

OBCI yields 4.80% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBCI wins by $4905.07M in total portfolio value
10 years
OBCI
OBCI
● Live price
4.80%
Share price
$13.03
Annual div
$0.63
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4905.10M
Annual income
$4,716,447,961.03
Full OBCI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — OBCI vs JNJ

📍 OBCI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBCIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBCI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBCI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBCI
Annual income on $10K today (after 15% tax)
$408.23/yr
After 10yr DRIP, annual income (after tax)
$4,008,980,766.88/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, OBCI beats the other by $4,008,976,780.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBCI + JNJ for your $10,000?

OBCI: 50%JNJ: 50%
100% JNJ50/50100% OBCI
Portfolio after 10yr
$2452.57M
Annual income
$2,358,226,325.21/yr
Blended yield
96.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OBCI
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBCI buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBCIJNJ
Forward yield4.80%2.13%
Annual dividend / share$0.63$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$4905.10M$30.3K
Annual income after 10y$4,716,447,961.03$4,689.40
Total dividends collected$4891.82M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OBCI vs JNJ ($10,000, DRIP)

YearOBCI PortfolioOBCI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,661$960.55$10,592$272.30+$1.1KOBCI
2$14,570$2,093.57$11,289$357.73+$3.3KOBCI
3$20,480$4,889.72$12,123$472.89+$8.4KOBCI
4$34,760$12,846.64$13,141$629.86+$21.6KOBCI
5$77,949$40,755.74$14,408$846.81+$63.5KOBCI
6$254,236$170,829.91$16,021$1,151.60+$238.2KOBCI
7$1,313,473$1,041,441.16$18,122$1,588.22+$1.30MOBCI
8$11,462,357$10,056,940.58$20,930$2,228.20+$11.44MOBCI
9$176,310,406$164,045,684.48$24,792$3,191.91+$176.29MOBCI
10$4,905,100,096$4,716,447,961.03$30,274$4,689.40+$4905.07MOBCI

OBCI vs JNJ: Complete Analysis 2026

OBCIStock

Ocean Bio-Chem, Inc. manufactures, markets, and distributes appearance, performance, and maintenance products for the marine, automotive, power sports, recreational vehicle, home care, and outdoor power equipment markets in the United States and Canada. The company offers marine products, including polishes, cleaners, protectants, waxes, enzyme fuel treatments, private label products, motor and teak oils, boat washes, vinyl and teak cleaners, bilge and hull cleaners, silicone and polyurethane sealants, polysulfide sealants, gasket materials, lubricants, antifouling additives, and anti-freeze coolants; and brushes, brush handles, tie-downs, and other related accessories. It also manufactures automotive products, such as fuel treatments for gas and diesel engines, motor oils, greases, and related items; anti-freeze and windshield washes; and automotive polishes, cleaners, and other items. In addition, the company offers fuel treatment and other specialty products to the recreational vehicle market; solutions to various problems associated with E-10 fuel; and other specialty recreational vehicle/power sports products, including cleaners, polishes, detergents, fabric cleaners and protectors, silicone sealants, waterproofers, gasket materials, degreasers, vinyl cleaners and protectors, toilet treatment fluids, and anti-freeze/coolants. Further, it provides solutions to rectify operating engine problems in commercial lawn, and other home and garden power equipment; deodorizers, disinfectants, and sanitizers, as well as mildew odor control bags and boat odor sanitizers; blends and packages chemical formulations; and manufactures PVC and HDPE blow molded bottles. The company sells its products under the Star Tron, Performacide, and Star brite brands through retailers and online retailers, as well as to distributors. Ocean Bio-Chem, Inc. was founded in 1973 and is headquartered in Fort Lauderdale, Florida. As of August 9, 2022, Ocean Bio-Chem, Inc. operates as a subsidiary of OneWater Marine Inc.

Full OBCI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this OBCI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBCI vs SCHDOBCI vs JEPIOBCI vs OOBCI vs KOOBCI vs MAINOBCI vs ABBVOBCI vs MRKOBCI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.